Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? Stefania MorgantiAntonio MarraGiuseppe Curigliano Review 06 February 2022 Pages: 465 - 484
Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go??? C. F. JacobsM. SoesanG. S. Sonke Review 07 February 2022 Pages: 485 - 489
Endocrine adherence in male versus female breast cancer: a seer-medicare review Azka AliZhigang XieKaren C. Daily Review 10 February 2022 Pages: 491 - 499
Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database Jessica BogachErin CordeiroTulin D. Cil Review 13 February 2022 Pages: 501 - 508
Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer Thi Truc Anh NguyenLauren M. PostlewaitXiaoxian Li Preclinical study 27 January 2022 Pages: 509 - 516
A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing Ilona FridmanLok ChanMarc D. Ryser Preclinical study 02 February 2022 Pages: 517 - 527
Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer Yousif KaririMichael S. TossEmad A. Rakha Preclinical study Open access 06 February 2022 Pages: 529 - 539
Diagnostic performance improvement with combined use of proteomics biomarker assay and breast ultrasound Su Min HaHong-Kyu KimJung Min Chang Clinical trial 27 January 2022 Pages: 541 - 552
Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05) Hwa Kyung ByunJae Sik KimYong Bae Kim Clinical trial 02 February 2022 Pages: 553 - 561
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience Alicia OkinesTazia IrfanNicholas C. Turner Clinical trial 04 February 2022 Pages: 563 - 571
Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers Jiqiao YangTao HeJie Chen Clinical trial 07 February 2022 Pages: 573 - 582
Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer Luc Y. DirixSteffi OeyenPeter B. Vermeulen Clinical trial Open access 08 February 2022 Pages: 583 - 591
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial Tamas HickishAjay MehtaLing-Ming Tseng Clinical trial Open access 09 February 2022 Pages: 593 - 602
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses E. PalassiniO. MirP. G. Casali Clinical trial 12 February 2022 Pages: 603 - 610
Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017 Jacqueline B. VoCody RaminLene Veiga Epidemiology Open access 02 February 2022 Pages: 611 - 622
The effect of emotional disorders on adherence to mammography screening guidelines Idil YazganAnees Chagpar Epidemiology 02 February 2022 Pages: 623 - 627
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients Po-Han LinShin-Cheh ChenChiun-Sheng Huang Epidemiology 03 February 2022 Pages: 629 - 637
Differences in somatic TP53 mutation type in breast tumors by race and receptor status Nijole C. PollockJohnny R. RamroopAmanda Ewart Toland Epidemiology 14 March 2022 Pages: 639 - 648
Examining the prevalence of homologous recombination repair defects in ER+ breast cancers Grace M. MooreSimon N. PowellAtif J. Khan Brief Communication 29 January 2022 Pages: 649 - 653
